Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: A randomized, double-blind, multicenter, placebo-controlled study

Journal of Clinical Psychiatry

Volumn 69, Issue 9, 2008, Pages 1437-1448

  Spencer, Thomas J ^a   Adler, Lenard A ^b   Weisler, Richard H ^c,d   Youcha, Sharon H ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e SHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; PLACEBO; SPD 465; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BACKACHE; BLOOD PRESSURE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MYALGIA; NAUSEA; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 52649137099     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n0911     Document Type: Article

References (35)

1. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163:716-723
2. Able SL, Johnston JA, Adler LA, et al. Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med 2007;37:97-107
3. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:187-201
4. Barkley RA. Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:233-260
5. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry 2006 Apr;67(4):524-540
6. Okie S. ADHD in adults. N Engl J Med 2006;354:2637-2641
7. Wilens TE. Drug therapy for adults with attention-deficit/hyperactivity disorder. Drugs 2003;63:2395-2411
8. O'Connor PJ. Improving medication adherence: challenges for physicians, payers, and policy makers. Arch Intern Med 2006;166:1802-1804
9. Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit/hyperactivity disorder. Int J Neuropsychopharmacol 2004;7:77-97
10. Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatry 2002;63(suppl 12):29-35
11. Ermer JC, Shojaei A, Pennick M, et al. Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release. Curr Med Res Opin 2007;23:1067-1075
12. Wigal T, Kollins S, Golarz H, et al. SPD465 Duration of effect: a prospective, double-blind, crossover study. Presented at the 53rd annual meeting of the American Academy of Child and Adolescent Psychiatry; Oct 26, 2006; San Diego, Calif
13. Wigal T, Childress A, Golarz H, et al. Clinical evaluation of SPD465, a novel ADHD compound. Presented at the 53rd annual meeting of the American Academy of Child and Adolescent Psychiatry; Oct 26, 2006; San Diego, Calif
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
15. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale-IV. New York, NY: The Guilford Press; 1998
16. Spencer TJ, Adler LA, McGough JJ, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2007 Jun;61(12):1380-1387
17. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001;58:775-782
18. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention-deficit/hyperactivity disorder. Am J Psychiatry 1998;155:693-695
19. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1995;52:434-443
20. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005;57:793-801
21. Guy W. Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
22. Adler LA, Sitt D, Faraone S, et al. Reliability and validity of the Time-Sensitive ADHD Symptom Scale (TASS) in adults. Presented at the 53rd annual meeting of the American Academy of Child and Adolescent Psychiatry; Oct 27, 2006; San Diego, Calif
23. Brown TE. Brown Attention-Deficit Hyperactivity Disorder Scales for Adolescents and Adults. Toronto, Ontario, Canada: The Psychological Corporation, Harcourt Assessment Canada; 1996
24. Brown TE. Executive functions and attention-deficit/hyperactivity disorder: implications of two conflicting views. Int J Disability Development and Education 2006;53:35-46
25. Barkley RA, Murphy KR, Fischer M. The Science of ADHD in Adults: Clinic-Referred Adults vs. Children Grown Up. New York, NY: Guilford Press; 2007
26. Biederman J, Petty C, Fried R, et al. Impact of psychometrically defined deficits of executive functioning in adults with attention-deficit/hyperactivity disorder. Am J Psychiatry 2006;163:1730-1738
27. Brown TE. Attention Deficit Disorder: The Unfocused Mind in Children and Adults. New Haven, Conn: Yale University Press; 2005
28. Hervey AS, Epstein JN, Curry JF. Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review. Neuropsychology 2004;18:485-503
29. Brown TE, Quinlan DM. Assessing the effects of OROS methylphenidate on executive function in adults with ADHD. Presented at the 56th American Psychiatric Association Institute on Psychiatric Services; Oct 6-10, 2004; Atlanta, Ga
30. Brown TE, Sutton VK, Rogers AE, et al. Atomoxetine alleviates executive function impairment associated with ADHD. Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, Ga
31. Landgraf JM. Monitoring quality of life in adults with ADHD: reliability and validity of a new measure. J Atten Disord 2007;11:351-362
32. Landgraf JM, Rich M, Rappaport L. Measuring quality of life in children with attention-deficit/hyperactivity disorder and their families: development and evaluation of a new tool. Arch Pediatr Adolesc Med 2002;156:384-391
33. Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213
34. Biederman J, Mick E, Faraone SV, et al. Influence of gender on attention-deficit/hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 2002;159:36-42
35. Goldman LS, Genel M, Bezman RJ, et al, for the Council on Scientific Affairs, American Medical Association. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998 Apr;279(14):1100-1107